Hexarelin vs PDA
Both Hexarelin and PDA are used for recovery. Here's how their evidence, dosing, and regulatory status actually compare.
Hexarelin
Evidence BHexarelin (HEX)
The strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.
View full Hexarelin profile →PDA
Evidence C+Pentadeca Arginate (PDA)
A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.
View full PDA profile →Side-by-Side
| Attribute | Hexarelin | PDA |
|---|---|---|
| Evidence Grade | B | C+ |
| FDA Status | Not FDA-approved — research compound (cardioprotective signals investigated) | Not FDA-approved — newer compounded analog of BPC-157 |
| Typical Dose | 100 mcg, 1–2 times daily (subcutaneous) | 200–500 mcg daily (subcutaneous) |
| Clinics Indexed | 41 | 41 |
| Categories | growth-hormone, recovery | recovery, anti-inflammatory |
Key reported benefits — Hexarelin
- ✓Strongest GH spike of GHRPs
- ✓Cardioprotective signals
- ✓Recovery
Key reported benefits — PDA
- ✓Tissue repair
- ✓Anti-inflammation
- ✓Potentially better stability than BPC-157
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.